Please Wait

Applying Filters...

Oxaliplatin
KDMF
Table View

Excipient Market Overview: Evonik launches high-purity excipients; India mandates disclosures from March 2026

Data Compilation
#PharmaFlow

Pipeline Prospector October 2025: Novartis to buy Avidity for US$ 12 bn; FDA approves Bayer’s med to treat hot flashes

Stock Recap
#PipelineProspector

Oxaliplatin

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

69 API Suppliers, 24 USDMF, 29 CEP/COS, 7 JDMF, 6 EU WC, 26 KDMF, 8 NDC API, 27 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

651 Drugs in Development

651 Drugs in Development

INTERMEDIATES

8 Intermediate Suppliers

8 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

282 FDF Dossiers, 69 FDA Orange Book, 136 Europe, 5 Canada, 6 Australia, 22 South Africa, 44 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

INJECTABLE;INTRAVENOUS - 100MG/20ML (5MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INTRAVENOUS - 200MG/40ML (5MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INTRAVENOUS - 50MG/10ML (5MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INTRAVENOUS - 100MG/20ML (5MG/ML), INJECTABLE;INTRAVENOUS - 50MG/10ML (5MG/ML)

RELATED EXCIPIENT COMPANIES

1 SPI Pharma, 2 Gangwal Healthcare, 1 Nanjing Well Pharmaceutical, 1 Capital Farma, 2 DFE Pharma, 9 Kerry, 2 Microlex e.U, 1 Pluviaendo, 1 Sigachi Industries

EXCIPIENTS BY APPLICATIONS

9 Fillers, Diluents & Binders, 7 Granulation, 5 Direct Compression, 2 Solubilizers, 2 Co-Processed Excipients, 1 Parenteral

DIGITAL CONTENT

45 News #PharmaBuzz

45 News #PharmaBuzz

GLOBAL SALES INFORMATION

16 US Medicaid Prescriptions, 44 Regulatory FDF Prices, 7 Annual Reports

MARKET PLACE

11 APIs, 18 FDF Dossiers

PATENTS & EXCLUSIVITIES

1 Health Canada Patents

1 Health Canada Patents

REF. STANDARDS & IMPURITIES

5 EDQM, 11 Others

$ Xls download

Filters

Log in to download the data

Last Updated on PharmaCompass	Virtual Booth	Country	Registrant Name	Registration No.	Compound	Registration Date	Manufacturer	Manufacturer's Country	Manufacturer's Address
31/10/2025	Fresenius Kabi AB Brunna	Sweden	Sangjin Trading Co., Ltd.	20250711-197-I-725-15	Oxaliplatin	2025-07-11	Fresenius Kabi Oncology Limited	India	D-35, industrial Area, Kalyani, Nadia, West Bengal-741 235, INDIA
31/10/2025	Fresenius Kabi AB Brunna	Sweden	Sangjin Trading Co., Ltd.	20121102-197-I-103-05	Oxaliplatin	2012-11-02	Fresenius Kabi Oncology Ltd.	India	D-35, Industrial Area Kalyani, Nadia, West Bengal - 741 235, India

Contact us
to update this info

Oxaliplatin

Oxaliplatin

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

69 API Suppliers

24 USDMF

29 CEP/COS

7 JDMF

6 EU WC

26 KDMF

8 NDC API

27 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

651 Drugs in Development

INTERMEDIATES

8 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

282 FDF Dossiers

69 FDA Orange Book

136 Europe

5 Canada

6 Australia

22 South Africa

44 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

INJECTABLE;INTRAVENOUS - 100MG/20ML (5MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

INJECTABLE;INTRAVENOUS - 200MG/40ML (5MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

INJECTABLE;INTRAVENOUS - 50MG/10ML (5MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

INJECTABLE;INTRAVENOUS - 100MG/20ML (5MG/ML)

INJECTABLE;INTRAVENOUS - 50MG/10ML (5MG/ML)

RELATED EXCIPIENT COMPANIES

1 SPI Pharma

2 Gangwal Healthcare

1 Nanjing Well Pharmaceutical

1 Capital Farma

2 DFE Pharma

9 Kerry

2 Microlex e.U

1 Pluviaendo

1 Sigachi Industries

EXCIPIENTS BY APPLICATIONS

9 Fillers, Diluents & Binders

7 Granulation

5 Direct Compression

2 Solubilizers

2 Co-Processed Excipients

1 Parenteral

DIGITAL CONTENT

45 News #PharmaBuzz

GLOBAL SALES INFORMATION

16 US Medicaid Prescriptions

44 Regulatory FDF Prices

7 Annual Reports

MARKET PLACE

11 APIs

18 FDF Dossiers

PATENTS & EXCLUSIVITIES

1 Health Canada Patents

REF. STANDARDS & IMPURITIES

5 EDQM

11 Others

Filters

INJECTABLE;INTRAVENOUS - 100MG/20ML (5MG/ML) Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

INJECTABLE;INTRAVENOUS - 200MG/40ML (5MG/ML) Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

INJECTABLE;INTRAVENOUS - 50MG/10ML (5MG/ML) Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons